BYSTOLIC 2.5 MG
NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) : 2.5 MG · DIN 02398990 · ABBVIE CORPORATION
Health Canada status: MARKETED
What is BYSTOLIC?
BYSTOLIC 2.5 MG contains NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) : 2.5 MG. It is listed in the Health Canada Drug Product Database under DIN 02398990, held by ABBVIE CORPORATION, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 19-Apr-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is BYSTOLIC used for?
Treatment of mild to moderate essential hypertension. May be used alone or concomitantly with thiazide diuretics or ACE inhibitors. Not for emergency treatment of hypertensive crises.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02398990 |
|---|---|
| Brand name | BYSTOLIC |
| Generic / active ingredient | NEBIVOLOL (NEBIVOLOL HYDROCHLORIDE) : 2.5 MG |
| Manufacturer | ABBVIE CORPORATION |
| Strength | 2.5 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C07AB12 NEBIVOLOL |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 19-Apr-2024 |
How is it administered?
Starting dose 5 mg once daily. May increase at 2-week intervals up to 20 mg once daily. Can be taken with or without food. Adjust dose for renal/hepatic impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (refer to full monograph), though section 11 is listed in the Table of Contents.
How is it supplied?
Bottles of 30 tablets (2.5, 5, and 10 mg) or 90 tablets (20 mg).
Contraindications
Hypersensitivity; severe bradycardia; cardiogenic shock; decompensated cardiac failure; 2nd/3rd degree AV block; sick sinus syndrome; severe hepatic impairment; severe peripheral arterial disorders.
Warnings and precautions
Do not abruptly cease therapy in CAD; may mask hypoglycemia/hyperthyroidism; caution in bronchospastic disease, peripheral artery disorders, and patients with conduction disorders.
What can be used instead?
Other Canadian products sharing ATC code C07AB12 NEBIVOLOL. 9 of 13 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| BYSTOLIC | 10 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02399016 |
| BYSTOLIC | 20 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02399024 |
| BYSTOLIC | 5 MG | TABLET | ABBVIE CORPORATION | MARKETED | DIN 02399008 |
| JAMP NEBIVOLOL | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02543508 |
| PRZ-NEBIVOLOL | 10 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548720 |
| PRZ-NEBIVOLOL | 2.5 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548704 |
| PRZ-NEBIVOLOL | 20 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548739 |
| PRZ-NEBIVOLOL | 5 MG | TABLET | PHARMARIS CANADA INC | MARKETED | DIN 02548712 |
| APO-NEBIVOLOL | 2.5 MG | TABLET | APOTEX INC | APPROVED | DIN 02492520 |
| APO-NEBIVOLOL | 20 MG | TABLET | APOTEX INC | APPROVED | DIN 02492547 |
Who else supplies NEBIVOLOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NEBIVOLOL appears in 415 registered pack listings across 11 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.